{
    "clinical_study": {
        "@rank": "13131", 
        "acronym": "COSTAN", 
        "brief_summary": {
            "textblock": "Multicenter, observational, longitudinal. The primary objective of the study is to evaluate\n      the impact of early RRMS treatment with Tysabri in anti-JCV antibody negative patients on\n      their quality of life (QoL) measured by MSIS-29 over 2 years.\n\n      The secondary objectives of the study are:\n\n        -  To evaluate the impact of early RRMS treatment with Tysabri in anti-JCV antibody\n           negative patients over 2 years on the following:\n\n             -  annualized relapse rate (ARR)\n\n             -  EDSS\n\n             -  work productivity\n\n             -  QoL by EQ-5D\n\n             -  QoL by Subject Global Assessment of Wellbeing VAS\n\n        -  To evaluate clinical disease-free status (relapses, EDSS) over 2 years The tertiary\n           objective of the study is to evaluate correlations between the endpoints.\n\n      Number of Subjects: 150 Study Population: Anti-JCV antibody negative RRMS patients who\n      either are treatment-na\u00efve with a highly active disease (\u2265 2 relapses in the year prior to\n      study entry and \u2265 1 Gd+ lesion on T1-weighted MRI at study entry) or have failed an adequate\n      course of their first-line disease modifying therapy (DMT), and who have been prescribed\n      Tysabri as per the labeling.\n\n      Treatment Groups: Single arm. Interim Analysis: An interim analysis will be performed at\n      month 12 of observation.\n\n      Visit Schedule: As per routine clinical practice. Efficacy Parameters: Passive collection of\n      ARR and EDSS at the scheduled visits.\n\n      Safety Parameters: As per routine pharmacovigilance."
        }, 
        "brief_title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis, Relapsing-Remitting", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "Multicenter, observational, longitudinal. The primary objective of the study is to evaluate\n      the impact of early RRMS treatment with Tysabri in anti-JCV antibody negative patients on\n      their quality of life (QoL) measured by MSIS-29 over 2 years.\n\n      The secondary objectives of the study are:\n\n        -  To evaluate the impact of early RRMS treatment with Tysabri in anti-JCV antibody\n           negative patients over 2 years on the following:\n\n             -  annualized relapse rate (ARR)\n\n             -  EDSS\n\n             -  work productivity\n\n             -  QoL by EQ-5D\n\n             -  QoL by Subject Global Assessment of Wellbeing VAS\n\n        -  To evaluate clinical disease-free status (relapses, EDSS) over 2 years The tertiary\n           objective of the study is to evaluate correlations between the endpoints.\n\n      Number of Subjects: 150 Study Population: Anti-JCV antibody negative RRMS patients who\n      either are treatment-na\u00efve with a highly active disease (\u2265 2 relapses in the year prior to\n      study entry and \u2265 1 Gd+ lesion on T1-weighted MRI at study entry) or have failed an adequate\n      course of their first-line disease modifying therapy (DMT), and who have been prescribed\n      Tysabri as per the labeling.\n\n      Treatment Groups: Single arm. Interim Analysis: An interim analysis will be performed at\n      month 12 of observation.\n\n      Visit Schedule: As per routine clinical practice. Efficacy Parameters: Passive collection of\n      ARR and EDSS at the scheduled visits.\n\n      Safety Parameters: As per routine pharmacovigilance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to understand the purpose and risks of the study and provide signed and dated\n             informed consent.\n\n          -  Age 18 to 65 years old, inclusive, at time of informed consent.\n\n          -  Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria [Polman\n             et al., 2011]).\n\n          -  Must have an EDSS score from 0 to 3.5, inclusive.\n\n          -  Anti-JCV antibody negative test within 3 months of Screening Visit or negative test\n             for anti-JCV antibody at Baseline Visit.\n\n          -  Must satisfy the approved therapeutic indications for Tysabri and the existing\n             reimbursement criteria as either 1st line (highly active) or 2nd line therapy in\n             respective provinces.\n\n          -  Must either be treatment na\u00efve with highly active disease (\u2265 2 relapses in the year\n             prior to study entry and \u2265 1 Gd+ lesion on T1-weighted MRI at study entry) or have\n             been treated with a single DMT (including Avonex, Betaseron, Rebif, Copaxone, or\n             Extavia) for \u226512 months and \u226418 months total prior to date of informed consent.\n\n          -  Decision to treat with Tysabri must precede enrollment.\n\n        Exclusion Criteria:\n\n          -  Any prior treatment with Tysabri.\n\n          -  Anti-JCV antibody positive at any timepoint.\n\n          -  Contraindications to treatment with Tysabri as described in the Product Monograph.\n\n          -  History of PML or other opportunistic infections, or an increased risk for such\n             infections.\n\n          -  History of diagnosis of Primary Progressive Multiple Sclerosis [PPMS] and/or\n             Secondary Progressive Multiple Sclerosis [SPMS].\n\n          -  Receiving immunomodulatory or immunosuppressive therapy.\n\n          -  Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate,\n             cyclophosphamide, mycophenolate, cladribine, rituximab).\n\n          -  Immunocompromised at the time of enrollment.\n\n          -  Known active malignancies (subjects with cutaneous basal cell carcinoma that has been\n             completely excised prior to study entry remain eligible).\n\n          -  Women breastfeeding, pregnant, or planning to become pregnant; women who are not\n             post-menopausal or surgically sterile who are unwilling to practice contraception.\n\n          -  Inability to comply with study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who choose to participate in the study will receive a thorough description of the\n        study protocol and an informed consent document describing the study and the risks and\n        benefits of participating. Recruitment will continue until approximately 150 patients have\n        been enrolled in the study at approximately 15 sites across Canada. Patients who withdraw\n        and complete the exit interview will not be eligible to re-enroll in the study. The\n        subject will be considered to be enrolled in the study once this identification number has\n        been generated. Patients who convert to anti-JCV antibody positive status during the\n        course of the study will be allowed to continue on Tysabri and in the study at the\n        discretion of the participating neurologi"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706107", 
            "org_study_id": "CAN-TYS-12-10333"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Quality of life", 
        "lastchanged_date": "September 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 2G3"
                    }, 
                    "name": "University of Alberta"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V8R 1J8"
                    }, 
                    "name": "Vancouver Island Health Authority"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint John", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E2L 4L2"
                    }, 
                    "name": "Saint John Regional Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 4K4"
                    }, 
                    "name": "Dalhousie MS Research Unit"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B1P 1P3"
                    }, 
                    "name": "Cape Breton Regional Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bracebridge", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P1L 2E1"
                    }, 
                    "name": "South Muskoka Medical Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5A5"
                    }, 
                    "name": "London Health Sciences Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "The Ottawa Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Sunnybrook Health Sciences Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gatineau", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J9J 0A5"
                    }, 
                    "name": "Clinique Neuro-Outaouais"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenfield Park", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J4V 2J2"
                    }, 
                    "name": "Neuro Rive-Sud"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "CHUM - Hopital Notre Dame"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3A 2B4"
                    }, 
                    "name": "McGill University - MNI"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }, 
                    "name": "Hopital Maisonneuve-Rosemont"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 5N4"
                    }, 
                    "name": "CHUS - Hopital Fleurimont"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients", 
        "overall_contact": {
            "email": "vladimir.migounov@biogenidec.com", 
            "last_name": "Vladimir Migounov"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Multiple Sclerosis Impact Scale-29", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706107"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Annualized Relapse Rate at each analysis timepoint and change from Baseline", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Expanded Disability Status Scale (EDSS) change over time", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Work Productivity and Activity Impairment at each analysis timepoint and change from Baseline", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "EuroQol 5-Dimension at each analysis timepoint and change from Baseline", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Subject Global Assessment of Wellbeing Visual Analog Scale at each analysis timepoint and change from Baseline", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Clinical Disease-Free Status (relapses, EDSS) at each analysis timepoint", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}